跳到正文
原文
Medical Xpress·· 8 天前精选AI 评分65

患者年龄可能影响黑色素瘤中驱动突变的作用

Patient age may shape which mutations drive melanoma

AI 导读

一项新研究发现,BRAF 突变在年轻患者中更可能导致黑色素瘤,而在老年患者中则较不常见;相反,NRAS 突变在老年患者中更为显著。这表明突变的重要性可能取决于患者的年龄,对精准医疗有重要影响。

推荐理由

研究揭示了不同年龄段患者中 BRAF 和 NRAS 突变在黑色素瘤中的作用差异,对精准医疗有重要影响。

正文
dermatologist
Credit: Unsplash/CC0 Public Domain

Precision medicine for cancer seeks to match treatment to the genetic changes found in a patient's tumor. A new Yale study suggests that for melanoma there may be an important clue to consider: the patient's age.

In the study published Nov. 6 in Science Advances, researchers found that one melanoma mutation in a gene called BRAF showed greater growth and persistence in tumors from younger patients but declined at older ages. Mutations in another cancer-associated gene, NRAS, showed the opposite trend, becoming more prominent with age.

These differences matter because precision medicine depends on identifying which alterations cancer relies on to grow out of control. The new findings suggest that a mutation's significance may depend not only on what the change is, but also on the age at which the cancer develops.

"For a young person, when they get a BRAF mutation, that is extremely likely to lead to melanoma. But for an older person, it's less likely, though still possible," says Yale Cancer Center's Jeffrey Townsend, Ph.D., senior author of the study. "This is important because there are therapies that target BRAF. It suggests they could be less effective in older patients than in younger ones."

The research offers strong evidence that age could play a key role in interpreting tumor genetics, developing targeted therapies and designing more informative clinical trials.

Modeling tumor selection

Cancer is a mass of cells, each acquiring hundreds of mutations. Some of these mutations may help a cancer cell replicate faster than its neighbors, giving it an advantage that allows cells carrying the mutation to become more prevalent in the tumor. High frequencies of a mutation were once assumed to indicate that cancer was gaining some type of advantage. Townsend says this is true in some cases; for example, the P53 gene is mutated at high frequencies in many cancers and plays a key role in tumor cell survival.

"But generally, the fact that a mutation is frequent in tumors doesn't necessarily mean it's important," says Townsend, Elihu professor of biostatistics at Yale School of Public Health and co-leader of the Genomics, Genetics, and Epigenetics Program at Yale Cancer Center. "It may also be frequent because that particular mutation happens within individual cells at a much faster rate than other mutations."

To understand if some of the frequent mutations found in melanoma were conferring an advantage, Townsend and his collaborators analyzed mutations in the BRAF and NRAS genes over time and modeled the association with age. The researchers used data from two publicly available databases—the Cancer Genome Atlas and the American Association for Cancer Research's Project GENIE—which contain data from thousands of patients.

Townsend and his team analyzed approximately 5,500 melanoma samples from people across all ages—some younger than 40, some middle-aged and some over the age of 60. Looking in each age group, the researchers calculated an index of how much growth and replication were happening in the cancer that wasn't happening elsewhere. They then used additional calculations to better understand how increasing age continuously altered the effects of the mutations.

"We used a computational framework that accounts for how frequently each mutation is expected to occur," says Yihan Liu, a third-year Ph.D. student in computational biology and biomedical informatics and co-author on the study. "This framework enabled us to estimate the strength of selection on these mutations."

The researchers found age-dependent selection, with NRAS mutations playing a more important role in the cancers of older individuals and BRAF mutations a more important role in younger people. However, this finding raised further questions about why these mutations are selected for at different ages.

Townsend says the findings align with emerging research that suggests cancer risk rises as we age not only due to the mutations in the cancer cells, but also due to damage and disorder in the noncancerous tissue around the cancer cells.

Cancer as an evolutionary system

Townsend's research lines up with that of other scientists who have recently started to characterize cancer, and even the human body itself, as an evolutionary system.

"You are actually the product of a dividing evolutionary tree of cells creating new cells, and that tree of evolution—that makes up your body—has incorporated lots of changes over time," says Townsend.

This evolutionary understanding of cancer also explains why cancer is so hard to treat. A tumor collects thousands of small mutations, many of which don't have an effect, while some allow the tumor to grow and spread. Finding any one target to block is very difficult, especially because the tumor may already have some cells that will be resistant to treatment.

Still, mapping the change in gene mutation over time could help oncologists tailor treatment through precision medicine.

"We should be aware when we do future clinical trials on drugs that target these mutations that their efficacy may be critically dependent on patient age," says Townsend. "Most clinical trial protocols exclude people with comorbidities, which can bias trial populations toward younger people. However, if the drug is approved, it is often used on older individuals, because they make up a greater proportion of those with cancer. Understanding which ages to assess these drugs for will be crucial for the success of future clinical trials."

Publication details

Yihan Liu et al., Age reshapes selection on melanoma driver mutations, Science Advances (2026). DOI: 10.1126/sciadv.aeh1407

Journal information: Science Advances

Key medical concepts

Melanoma

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Patient age may shape which mutations drive melanoma (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-patient-age-mutations-melanoma.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com